<DOC>
	<DOCNO>NCT00479167</DOCNO>
	<brief_summary>The purpose study determine dose bortezomib combination tositumomab I-131 tolerable whether bortezomib Tositumomab I-131 effective treatment relapse refractory non-hodgkin 's lymphoma ( NHL ) . Both agent effective treat relapsed refractory NHL . Administer agent together may sensitize cell radiation Tositumomab I-131 .</brief_summary>
	<brief_title>A Phase II Trial Combined Weekly Bortezomib Tositumomab I-131 Patients With Relapsed Refractory Follicular Non-Hodgkin 's Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Follicular</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Iodine-131 anti-B1 antibody</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Previously treat relapse follicular lymphoma . One prior therapy require . Bidimensionally measurable disease least one lesion measure &gt; 2.0 X 2.0cm CT scan evaluable disease . CD20+ time diagnosis subsequently . Platelet count &gt; 100,000/uL , ANC &gt; 1000/uL . Transaminases less twofold normal range . Adequate renal function define &lt; 1.5 X upper limit normal HAMA negative ECOG performance status 0 , 1 , 2 . Female subject either postmenopausal surgically sterilize willing use acceptable method birth control ( i.e. , hormonal contraceptive , intrauterine device , diaphragm spermicide , condom spermicide , abstinence ) duration study . Male subject agrees use acceptable method contraception duration study . Negative Hepatitis profile screen Myocardial infarction within 6 month prior enrollment New York Heart Association ( NYHA ) Class III IV heart failure ( see section 8.4 ) , uncontrolled angina , severe uncontrolled ventricular arrhythmia , electrocardiographic evidence acute ischemia active conduction system abnormality . Prior study entry , ECG abnormality Screening document investigator medically relevant . Patient hypersensitivity boron mannitol . Greater 25 % intratrabecular marrow space involve lymphoma bone marrow biopsy specimens Hypocellular bone marrow ( ≤15 % cellularity mark reduction bone marrow precursor ) . Prior myeloablative therapy . History fail stem cell collection . Prior radiotherapy field encompass 25 % bloodforming marrow . Prior chemotherapy , biologic therapy , radiation therapy steroid therapy NHL within three week prior screen procedure . Six week nitrosureas . Subjects receive low dos steroid nonneoplastic indication may enter study ( `` low dose steroid '' define ≤10 mg prednisone equivalent per day ) . Prior Radioimmunotherapy bortezomib . Prior malignancy lymphoma , except adequately treat basal cell squamous cell skin cancer , situ uterine cervical cancer , cancer subject diseasefree five year . Evidence active infection require intravenous antibiotic time study enrollment . Known HIV infection . Known brain leptomeningeal metastasis . Active obstructive hydronephrosis . Known Type I hypersensitivity anaphylactic reaction murine protein component Iodine I 131 tositumomab therapeutic regimen . Female subject pregnant breastfeeding . Confirmation subject pregnant must establish negative serum pregnancy test result obtain screening . Pregnancy test require postmenopausal surgically sterilize woman . Patient receive investigational drug 14 day enrollment Serious medical psychiatric illness likely interfere participation clinical study . Patient Grade 2 peripheral neuropathy within 14 day enrollment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2009</verification_date>
	<keyword>Non-Hodgkin 's Lymphoma</keyword>
	<keyword>Follicular Non-Hodgkin 's Lymphoma</keyword>
	<keyword>Lymphoma</keyword>
</DOC>